((RAIN)) Rainmakers-Island

[The Rainmaker]

TLTFF Story: Roger Dumoulin-White was a senior executive for Ford Electronics Manufacturing Corporation, a division of Ford Motor Company, running a $30 million a year business for Ford with 400 employees reporting to him Life was good for Roger, or so it seemed, and then a call came, which would change his life forever. In 1993, Roger’s father, a jeweler called him one evening to proclaim that he had been introduced to a new medical technol-ogy and wanted to speak to Roger about it. Roger travelled to his father’s jewelry store for a meeting. His father stated that he has met an inventor in Belgium, who had devel-oped a therapeutic laser that was able to heal tissue. Roger the penultimate skeptic, asked to see it. Oddly enough, his father stated that he couldn’t show it to him because it was an invisible laser. Now Roger was really skepti-cal and thought that his father had gone off the proverbial deep end. Roger persisted and his father produced a rough prototype of a medical laser that produced an invisible laser light. His father proceeded to place it on his own arm to demonstrate and Roger instantly snatched it out of his father’s hand proclaiming, “Dad, if it is a laser, it will burn you. Lasers burn tissue.” His father claimed that it healed tissue and Roger tired from the banter, and clearly not convinced, stated that he had to leave, as he had to work early the next morning. His Dad produced a one page document, translated from Flemish, which detailed how fibroblasts (the building blocks of connective tissue, like tendons) had an increased mitosis rate (cell division leading to growth of new tissue) of 100% under the influence of this mystery invisible laser light.Roger took this page and pondered on the drive home, “How on earth could an invisible laser light influence the growth of biological tissue?” After all, we are not plants, we don’t require sunlight to complete photosynthesis. Roger being a technical person at heart decided to research this phenomenon to see if it had any validity. After a year and of due diligence, Roger had discovered that this technology had merit. It was in its infancy in Europe, was unheard of in North America, but had solid scientific data supporting its biological effect on tissue, although not well understood by scientific researchers or med-ical doctors.Roger flew to Belgium in July 1994, met the inventor, the doctors who were using it and the patients who were being treated and fell in love with the technology. He negotiat-ed the worldwide exclusive rights to the tech-nology and flew back to Toronto where he walked into head office for Ford Electronics and promptly resigned his position, start-ing Theralase from scratch August 1, 1994.

TLTFF, OTC) was born.Roger’s research indicated that this tech-nology had the power to heal tissue with none of the side effects of surgery or phar-maceutical drugs, such as ineffective treat-ments, long healing times, scar tissue or addictions. His vision was to design, manufacture and distribute a therapeutic laser which met the stringent criteria of Western medicine and delivered safe and effective treatments to patient’s suffering from a wide range of nerve, muscle and joint conditions.Theralase designed 3 successively more effective therapeutic laser platforms, the TLC-500, the TLC-1000 (which completed $2 M in sales in 2015) and now the TLC-2000, which uses patented CellSensing® tech-nology to automatically detect injured tissue and adjust the power and time (“doseher research. Again, Roger fell in love with the technology, flew to Virginia Tech (“VT”) in Blacksburg, Virginia and negotiated the worldwide exclusive rights to the technology.Roger set to work designing laser systems that could activate these next generation anti-cancer drugs; however, something was missing, where would the technology be used to treat patients? What type of cancer patient would respond best to the technol-ogy? Roger then negotiated a working rela-tionship with one of the top 3 research can-cer institutes in the world, the elite Princess Margaret Cancer Centre, part of University Health Network (“UHN”) based in Toronto”) of laser light based on a patient’s physical characteristics (skin color, subcutaneous fat, muscle thickness, etc.) to deliver effective treatments with healing rates in excess of 90%. In 2000, Roger was reading an obscure article in a trade magazine called Laser Focus World where he read a two line article about a female chemistry professor that was starting to develop new drugs called Photo Dynamic Compounds (“
PDC
”), which had an attraction to cancer cells and when light activated could destroy the cancer cell from the inside out.This caught Roger’s eye and he wrote to the researcher of his interest. She sent her latest research on the subject and Roger couldn’t understand a word about the tech-nology, but after a year of due diligence and research was able to partially understand the complex chemical formulas that comprised her research. Again, Roger fell in love with the technology, flew to Virginia Tech (“
VT
”) in Blacksburg, Virginia and negotiated the worldwide exclusive rights to the technology.Roger set to work designing laser systems that could activate these next generation anti-cancer drugs; however, something was missing, where would the technology be used to treat patients? What type of cancer patient would respond best to the technol-ogy? Roger then negotiated a working rela-tionship with one of the top 3 research can-cer institutes in the world, the elite Princess Margaret Cancer Centre, part of University Health Network (“
UHN”) based in Toronto Canada.The trilogy was now complete, VT would design and manufacture the PDCs, Theralase would manufacture the lasers to effectively activate them and UHN would test the com-bination on cancer patients to prove their safety and efficacy.In 2012, Theralase and VT won the Popular Mechanics Award for one of the best ten technologies in the United States. There were numerous announcements and media coverage, which caught the attention of another female chemistry professor from Acadia University in Nova Scotia, Canada, who was also designing and developing PDCs. She contacted Roger and Roger now fully versed on the PDC science, reviewed her research and again fell in love with the technology, negotiating the worldwide exclu-sive rights to this new platform of PDCs.Theralase the penultimate visionary acquired the worldwide exclusive rights to two groundbreaking technologies: therapeu-tic lasers to heal pain and PDCs to destroy cancer.Roger then set upon hiring the right engineers, sales and marketing professionals, scientific researchers and clinical staff to build the Company, but quickly realized that these high priced heads all cost signifi-cant money, so in 2003 Roger negotiated a Reverse Takeover with a public shell and took the Company public raising a small amount of funds at the time.Fast forward to today, multiple rounds of financing and strategic hiring has placed the Company on the cusp of greatness. It received Health Canada and FDA approval of its next generation TLC-2000 therapeu-tic laser with CellSensing® technology in December 2015 and is strategically roll-ing this technology out in Canada and the United States. Theralase expects to grow this division into $50 million annually in the next 5 years as it enters mainstream medicine in the United States. Theralase is also commencing a Phase Ib first-in-man clinical trial for Non-Muscle Invasive Bladder Cancer (“NMIBC”) in August 2016 at UHN, pending Health Canada approval of its laser system used to activate the PDC.

The US pain market is estimated at $100 billion dollars annually and growing rapidly with the aging population, a large address-able market.The US cancer market for NMIBC is esti-mated at $4 billion annually and Theralase expects to secure 25% of this market on commercialization of its anti-cancer tech-nology at the end of 2018.So Theralase after 22 years of hard work has finally reached an inflection point and is set to attack 2 multi-billion dollar behe-moths in the world; namely, eliminating pain and destroying cancer.To complete these daunting tasks, Theralase has hired a direct sales and mar-keting force in Canada and the United States to sell its next generation therapeutic laser and has signed agreements to work with one of the top 3 cancer research institutes in the world to prove that its next generation anti-cancer technology has the ability to safely and effectively destroy cancer. As a bonus, the PDC technology has demonstrated the ability to prevent cancer recurrence through an immune mediated response that vac-cinates the patient against further cancer attacks. An elegant one-two punch to a dead-ly disease, destroying the primary tumour, one, and then preventing its recurrence, two and knockout.Further developments for the Company include commencing research into the destruction of lung cancer and brain cancer with its next generation anti-cancer technology later this year.

Starts on Page 36

http://stocknewsnow.com/microcapreview-issue.php?id=323021052